Breast Cancer Detection
Implementing our innovative breath test as an adjunct to mammography screening for women with dense breast tissue has the potential to find more cancer sooner.
Early disease detection
could be as easy as breathing.
We are on a mission to revolutionize early cancer detection with our innovative breath analytics platform technology.
Our primary focus is to develop a breath test to be used as an adjunct to mammography screening to detect early-stage breast cancer in women with dense breast tissue.
Women who have dense breast tissue are four to five times more likely to develop breast cancer and the sensitivity of screening mammography can be as low as 30% in women with extremely dense breast tissue.
Results of Breathe BioMedical Inc.’s most recent research supports the potential of our technology. Our study identified differences in the breath signatures of women with early-stage breast cancer compared to those without breast cancer with 88.2% accuracy. A sub-group analysis found that breast tissue density had no significant effect on accuracy.
Early breast cancer detection saves lives. Our technology could make early detection easier, faster and more accessible than ever before.
Just breathe®
Learn More
The Science of Breath Analytics
Breath analytics has the potential to play a pivotal role in early disease detection and improving outcomes by detecting health issues before symptoms appear.
The Leaders Making it Happen
Breathe BioMedical’s leadership team has decades of experience in developing and commercializing medtech and diagnostics innovations.
Biomarkers in Breath
There’s much more in exhaled breath than most realize. Find out more about how our breath analytics technology may change how and when disease can be detected.
Learn More
